Subtitle: Comprehensive WHO-based review of undifferentiated round cell sarcoma covering BCOR, CIC, and EWSR1 fusion sarcomas. Includes histopathology, immunohistochemistry, molecular genetics, diagnosis, prognosis, treatment, and MCQs

Category: Soft Tissue Pathology
Author: PathologyMCQ Team
Last Updated: January 2026
Read Time: 14–16 minutes

At a Glance

• Rare WHO-defined non-Ewing small round blue cell sarcoma driven by BCOR, CIC and EWSR1 non-ETS fusions
• Requires mandatory molecular testing because morphology and CD99 alone are unreliable
• Prognosis varies by subtype, with CIC-rearranged tumors being the most aggressive

Table of Contents

1. Introduction to Undifferentiated Round Cell Sarcoma
2. WHO Molecular Classification of Undifferentiated Round Cell Sarcomas
3. Molecular Genetics Behind Small Round Blue Cell Tumors
4. Histopathology and Immunohistochemistry Features
5. Clinical Presentation and Diagnostic Approach
6. Prognosis and Treatment Approaches
7. High-Yield MCQs
8. Exam Pearls
9. Key Takeaways
10. Recommended Learning

1. Introduction to Undifferentiated Round Cell Sarcoma

Undifferentiated round cell sarcoma (URCS) represents a heterogeneous group of malignant mesenchymal tumors composed of primitive round to oval cells that lack definitive line of differentiation on routine histology.

These tumors fall under the umbrella of small round blue cell tumors, a morphologic category that also includes Ewing sarcoma, rhabdomyosarcoma, lymphoma, neuroblastoma, and desmoplastic small round cell tumor. The diagnostic challenge arises because these entities can appear deceptively similar under light microscopy while behaving very differently clinically.

For decades, many undifferentiated round cell sarcomas were misclassified as Ewing sarcoma. The advent of molecular diagnostics has demonstrated that a substantial subset of these tumors lack the canonical EWSR1–ETS fusions, instead harboring distinct genetic alterations that justify their recognition as separate WHO-defined entities.

2. WHO Molecular Classification of Undifferentiated Round Cell Sarcomas

The WHO 2020–2024 classification of soft tissue tumors formally recognizes undifferentiated round cell sarcomas as a molecularly defined group, distinct from classic Ewing sarcoma.

WHO-Recognized Molecular Subgroups

Subtype	Defining Genetic Alteration
CIC-rearranged sarcoma	CIC–DUX4 fusion
BCOR-altered sarcoma	BCOR–CCNB3 fusion or BCOR internal tandem duplication
EWSR1 non-ETS fusion sarcomas	EWSR1–NFATC2, EWSR1–PATZ1, EWSR1–VEZF1

This classification is clinically significant because:

• Morphology alone is unreliable
• Immunohistochemistry shows overlap
• Prognosis varies dramatically by subtype
• Treatment response differs from Ewing sarcoma

3. Molecular Genetics Behind Small Round Blue Cell Tumors

Undifferentiated round cell sarcomas are fundamentally genetically driven tumors. Their biology is dictated by transcriptional dysregulation resulting from oncogenic gene fusions.

Key Molecular Alterations

Fusion / Alteration	Molecular Mechanism	Clinical Relevance
CIC–DUX4	Aberrant transcriptional activation	Highly aggressive
BCOR–CCNB3	Cell cycle dysregulation	Intermediate prognosis
BCOR ITD	Epigenetic dysregulation	Pediatric predominance
EWSR1–NFATC2	Oncogenic transcription factor	Locally aggressive
EWSR1–PATZ1	Transcriptional repression	Emerging entity

These fusions lead to profound reprogramming of gene expression, explaining why tumors with similar morphology behave differently.

Histology Molecular Subtypes

Round Cell Sarcoma with EWSR1 Non-ETS Fusions

EWSR1–NFATC2 Fusion Sarcoma – Epithelioid Morphology

EWSR1–NFATC2 fusion sarcomas typically show epithelioid or spindle-epithelioid tumor cells arranged in cords or nests within a fibrous stroma. Despite relatively bland cytology, these tumors are often locally aggressive, frequently involving bone or deep soft tissues. CD99 expression may be present but is inconsistent, making molecular confirmation essential.

EWSR1–PATZ1 Fusion Sarcoma – Diffuse Round to Oval Cells

EWSR1–PATZ1 fusion sarcomas display diffuse sheets of round to oval undifferentiated cells, closely mimicking Ewing sarcoma and other small round blue cell tumors. Because of this overlap, these tumors are commonly misdiagnosed without molecular testing.

4. Histopathology and Immunohistochemistry Features

General Histologic Features

• Sheets or nests of small round to oval cells
• Scant cytoplasm
• Hyperchromatic nuclei
• Frequent mitoses
• Variable necrosis

Immunohistochemistry Overview

Subtype	Typical IHC Profile
CIC-rearranged	WT1+, ETV4+, CD99 variable
BCOR sarcoma	BCOR+, CCNB3+, SATB2+
EWSR1–NFATC2	CD99+, NKX2.2 variable
EWSR1–PATZ1	CD99+, desmin occasional

⚠️ CD99 positivity is not diagnostic and must never be used in isolation.

BCOR and CIC Tumors

Sarcoma with BCOR Genetic Alterations – Spindle Cell Morphology

BCOR-altered sarcomas frequently exhibit spindle-shaped tumor cells arranged in fascicles or sheets, distinguishing them morphologically from classic Ewing sarcoma. The presence of BCOR nuclear positivity and CCNB3 expression strongly supports the diagnosis. These tumors generally show better outcomes compared to CIC-rearranged sarcomas.

CIC-Rearranged Sarcoma – Marked Cytologic Atypia

CIC-rearranged sarcomas show marked nuclear pleomorphism, prominent nucleoli, brisk mitotic activity, and necrosis. These features correlate with the aggressive clinical course and poor prognosis characteristic of this subtype.

5. Clinical Presentation and Diagnostic Approach

Clinical Features

• Predominantly children and young adults
• Deep soft tissue or bone involvement
• Rapidly enlarging painful mass

Diagnostic Algorithm

1. Radiologic evaluation (MRI or CT)
2. Core needle biopsy
3. Histopathology + IHC panel
4. Mandatory molecular testing by FISH or NGS

Differential Diagnosis

• Ewing sarcoma
• Rhabdomyosarcoma
• Lymphoblastic lymphoma
• Neuroblastoma

6. Prognosis and Treatment Approaches

Subtype	Prognosis	Key Notes
CIC-rearranged	Poor	High metastatic potential
BCOR-altered	Intermediate	Better chemotherapy response
EWSR1–NFATC2	Variable	Locally aggressive

Treatment Modalities

• Wide surgical excision
• Multi-agent chemotherapy
• Radiotherapy for local control

7. High – yield MCQS

8. Exam Pearls

• Small round blue cell tumor is not always Ewing sarcoma
• CIC-rearranged sarcoma is the most aggressive
• BCOR sarcomas have better prognosis
• CD99 positivity is non-specific
• Molecular testing is mandatory

9. Key Takeaways

• URCS is a WHO-defined molecular entity
• Diagnosis requires genetic confirmation
• Prognosis varies by molecular subtype

10. Recommended Learning